Breaking News Instant updates and real-time market news.

INSY

Insys Therapeutics

$5.24

-0.13 (-2.42%)

09:26
12/07/17
12/07
09:26
12/07/17
09:26

Insys Therapeutics starts proof-of-concept study of epinephrine nasal spray

INSYS Therapeutics announced that it has started a proof-of-concept study of two formulations of epinephrine nasal spray for the treatment of anaphylaxis, or severe allergic reaction, with the enrollment of the first patient. This Phase 1 clinical trial is designed to establish whether intranasal administration of epinephrine is bioequivalent to the standard method of delivering the drug, which is through intramuscular injection.

INSY Insys Therapeutics
$5.24

-0.13 (-2.42%)

03/24/17
JANY
03/24/17
NO CHANGE
Target $19
JANY
Buy
Janney says Insys receipt of DEA decision removes 'stonewalling' fear
Janney Capital analyst Ken Trbovich said Insys Therapeutics' receipt of DEA scheduling of Syndros sets up a launch in the second half of the year, giving its sales reps a second product to promote and the company an opportunity to return to growth. Furthermore, the decision removes uncertainty about whether the company's ongoing DOJ investigation led to "stonewalling" of the company's regulatory efforts, noting that "while slow," both the DEA and FDA eventually took action. He keeps a Buy rating and $19 fair value estimate on Insys shares.
04/06/17
OPCO
04/06/17
NO CHANGE
OPCO
Perform
DoJ settlement not 'end all, be all' for Insys Therapeutics, says Oppenheimer
Oppenheimer analyst Derek Archila thinks Insys Therapeutics' shares are likely to react favorably on an announcement of a DoJ settlement, but he does not view it as the "end all, be all" clearing event for the company as he continues to worry about deteriorating Subsys sales and consensus forecasts for Syndros that look too high. The analyst reiterates a Perform rating on the shares.
05/10/17
PIPR
05/10/17
DOWNGRADE
Target $10
PIPR
Neutral
Insys Therapeutics downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Neutral following the Q1 results and halved his price target for the shares to $10 from $20. Prescription trends for Subsys have been consistently weak and will remain so given the scrutiny of the opioid space and Insys in particular, Amsellem tells investors in a post-earnings research note.
07/21/17
JANY
07/21/17
NO CHANGE
Target $16
JANY
Buy
Subsys ANDA somewhat negative for Insys, but not unexpected, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA's Paragraph IV certifications list earlier this week showed that Insys had received an ANDA filing for Subsys on May 22, which he views as "somewhat negative," but also "not unexpected." While the ANDA raises the possibility of a generic sooner rather than later, Trbovich sees no risk for a generic Subsys until 2020 at the earliest and thinks the company's patents could prevent generic entry until as late as 2030. He keeps a Buy rating and $16 fair value estimate on Insys shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.